KYOWA KIRIN CO., LTD.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1949-07-01
- Employees
- 5.9K
- Market Cap
- -
- Website
- http://www.kyowa-kirin.co.jp
A Study to Evaluate Abuse Potential of Istradefylline
Phase 1
Completed
- Conditions
- Drug Abuse
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02609477
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc, Salt Lake City, Utah, United States
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Phase 3
Completed
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 239
- Registration Number
- NCT02610231
- Locations
- π¨πΏ
Kwoya PD Site, Brno, Czechia
π·πΈKyowa PD Site 4, Belgrade, Serbia
π·πΈKyowa PD Site, Novi Sad, Serbia
Phase 3 Study of KHK7580
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 634
- Registration Number
- NCT02549391
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan
Phase 3 Study of KHK7580
Phase 3
Completed
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Drug: KHK7580
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 137
- Registration Number
- NCT02549404
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan
Phase 3 Study of KHK7580
Phase 3
Completed
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Drug: KHK7580
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT02549417
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan
Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumor
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT02476123
A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02377713
The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study
Phase 2
Completed
- Conditions
- Chronic Kidney DiseaseType 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 216
- Registration Number
- NCT02316821
Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02256033
- Locations
- πΊπΈ
Noccr/Vrg, Knoxville, Tennessee, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
Phase 2 Study of KHK7580
Phase 2
Completed
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT02216656
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo, Japan
Β© Copyright 2025. All Rights Reserved by MedPath